BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 63 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $14,587,500 | -1.2% | 15,000,000 | 0.0% | 0.69% | +19.7% |
Q2 2023 | $14,771,520 | -4.3% | 15,000,000 | 0.0% | 0.57% | -15.7% |
Q1 2023 | $15,427,185 | -59.6% | 15,000,000 | -58.2% | 0.68% | -50.2% |
Q4 2022 | $38,201,058 | -16.2% | 35,910,000 | -21.8% | 1.37% | -17.1% |
Q3 2022 | $45,604,000 | +0.1% | 45,910,000 | 0.0% | 1.65% | -5.1% |
Q2 2022 | $45,566,000 | -0.9% | 45,910,000 | 0.0% | 1.74% | +1.0% |
Q1 2022 | $46,002,000 | -4.4% | 45,910,000 | 0.0% | 1.72% | +5.0% |
Q4 2021 | $48,118,000 | +0.9% | 45,910,000 | 0.0% | 1.64% | +16.8% |
Q3 2021 | $47,675,000 | -0.3% | 45,910,000 | 0.0% | 1.40% | -6.5% |
Q2 2021 | $47,834,000 | +1.0% | 45,910,000 | 0.0% | 1.50% | +3.7% |
Q1 2021 | $47,356,000 | +9.6% | 45,910,000 | +13.9% | 1.45% | -4.9% |
Q4 2020 | $43,210,000 | +2.0% | 40,300,000 | 0.0% | 1.52% | -22.4% |
Q3 2020 | $42,361,000 | -17.3% | 40,300,000 | -3.1% | 1.96% | -26.2% |
Q2 2020 | $51,199,000 | +17.9% | 41,600,000 | 0.0% | 2.66% | -25.5% |
Q1 2020 | $43,421,000 | – | 41,600,000 | – | 3.57% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
KBC Group NV | 400,000 | $40,316,000 | 0.15% |
PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |